BR0015534A - Tratamento da densidade mineral óssea subnormal - Google Patents

Tratamento da densidade mineral óssea subnormal

Info

Publication number
BR0015534A
BR0015534A BR0015534-9A BR0015534A BR0015534A BR 0015534 A BR0015534 A BR 0015534A BR 0015534 A BR0015534 A BR 0015534A BR 0015534 A BR0015534 A BR 0015534A
Authority
BR
Brazil
Prior art keywords
treatment
bone mineral
mineral density
individual
agent
Prior art date
Application number
BR0015534-9A
Other languages
English (en)
Inventor
Kenneth E Schwartz
Original Assignee
Genelabs Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genelabs Tech Inc filed Critical Genelabs Tech Inc
Publication of BR0015534A publication Critical patent/BR0015534A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"TRATAMENTO DA DENSIDADE MINERAL óSSEA SUBNORMAL". Apresenta-se um método para tratamento de um indivíduo com a finalidade de aumentar a densidade mineral óssea (BMD) do indivíduo. O método inclui a co-administração de um agente similar à calcitonina e um agente similar à DHEA. Revelam-se também métodos para potencializar o efeito do tratamento com um agente similar à calcitonina na BMD e para o aumento da BMD num indivíduo em tratamento com DHEA, por exemplo, para tratamento do lúpus eritematoso sistêmico (SLE).
BR0015534-9A 1999-11-12 2000-11-13 Tratamento da densidade mineral óssea subnormal BR0015534A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16508999P 1999-11-12 1999-11-12
US09/710,729 US6605591B1 (en) 1999-11-12 2000-11-10 Treatment of subnormal bone mineral density
PCT/US2000/030131 WO2001035975A2 (en) 1999-11-12 2000-11-13 Treatment of subnormal bone mineral density

Publications (1)

Publication Number Publication Date
BR0015534A true BR0015534A (pt) 2002-07-02

Family

ID=26861107

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0015534-9A BR0015534A (pt) 1999-11-12 2000-11-13 Tratamento da densidade mineral óssea subnormal

Country Status (16)

Country Link
US (3) US6605591B1 (pt)
EP (1) EP1231983B1 (pt)
JP (1) JP2003514026A (pt)
KR (1) KR20020063183A (pt)
CN (1) CN1411386A (pt)
AT (1) ATE326265T1 (pt)
AU (1) AU784160B2 (pt)
BR (1) BR0015534A (pt)
CA (1) CA2390431A1 (pt)
DE (1) DE60028074D1 (pt)
IL (1) IL149532A0 (pt)
MX (1) MXPA02004776A (pt)
NO (1) NO20022246L (pt)
NZ (1) NZ518791A (pt)
RU (1) RU2002115815A (pt)
WO (1) WO2001035975A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605591B1 (en) * 1999-11-12 2003-08-12 Genelabs Technologies, Inc. Treatment of subnormal bone mineral density
US7660453B2 (en) 2000-10-11 2010-02-09 Imaging Therapeutics, Inc. Methods and devices for analysis of x-ray images
US8639009B2 (en) 2000-10-11 2014-01-28 Imatx, Inc. Methods and devices for evaluating and treating a bone condition based on x-ray image analysis
DE60233485D1 (de) 2001-05-25 2009-10-08 Imaging Therapeutics Inc Verfahren zur diagnose, behandlung und prävention von knochenverlust
US7840247B2 (en) * 2002-09-16 2010-11-23 Imatx, Inc. Methods of predicting musculoskeletal disease
US8965075B2 (en) * 2002-09-16 2015-02-24 Imatx, Inc. System and method for predicting future fractures
EP1605824A2 (en) 2003-03-25 2005-12-21 Imaging Therapeutics, Inc. Methods for the compensation of imaging technique in the processing of radiographic images
US20050014734A1 (en) * 2003-07-18 2005-01-20 Genovate Biotechnology Co., Ltd. Modulation of interleukin-10 by DHEA
US20080058613A1 (en) * 2003-09-19 2008-03-06 Imaging Therapeutics, Inc. Method and System for Providing Fracture/No Fracture Classification
CA2580726A1 (en) 2004-09-16 2006-03-30 Imaging Therapeutics, Inc. System and method of predicting future fractures
PT2460515T (pt) * 2007-08-09 2017-04-27 Novartis Ag Composições orais de calcitonina e suas aplicações
AU2009253839B2 (en) * 2008-06-03 2011-07-28 John Ray Biffin A method for increasing bone density and/or reducing any osteochondral defects in an animal and a composition including vitamin K
US8939917B2 (en) 2009-02-13 2015-01-27 Imatx, Inc. Methods and devices for quantitative analysis of bone and cartilage

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175146A (en) 1989-12-05 1992-12-29 Vical, Inc. Synthetic calcitonin peptides
WO1994008589A1 (en) 1992-10-09 1994-04-28 The Board Of Trustees Of The Leland Stanford Junior University Treatment of systemic lupus erythematosus with dehydroepiandrosterone
US5776923A (en) 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
AU743121B2 (en) 1996-11-25 2002-01-17 Merck & Co., Inc. Androgenic and bisphosphonic agents coadministered to treat diseases
KR20000071039A (ko) * 1997-02-13 2000-11-25 비숍 찰스 더블유. 비타민 ｄ 화합물의 표적화된 치료학적 전달
CN100544726C (zh) 1999-03-18 2009-09-30 基因实验室技术公司 Dhea制剂及方法
US7045513B1 (en) 1999-03-18 2006-05-16 Genelabs Technologies, Inc. DHEA composition and method
US6605591B1 (en) * 1999-11-12 2003-08-12 Genelabs Technologies, Inc. Treatment of subnormal bone mineral density

Also Published As

Publication number Publication date
WO2001035975A2 (en) 2001-05-25
ATE326265T1 (de) 2006-06-15
RU2002115815A (ru) 2004-02-27
KR20020063183A (ko) 2002-08-01
US20050113301A1 (en) 2005-05-26
WO2001035975A3 (en) 2001-12-27
DE60028074D1 (de) 2006-06-22
US7612034B2 (en) 2009-11-03
EP1231983B1 (en) 2006-05-17
US20030158159A1 (en) 2003-08-21
CA2390431A1 (en) 2001-05-25
AU1580201A (en) 2001-05-30
EP1231983A2 (en) 2002-08-21
CN1411386A (zh) 2003-04-16
NZ518791A (en) 2004-03-26
JP2003514026A (ja) 2003-04-15
NO20022246L (no) 2002-07-03
AU784160B2 (en) 2006-02-16
IL149532A0 (en) 2002-11-10
MXPA02004776A (es) 2003-01-28
US6854468B2 (en) 2005-02-15
US6605591B1 (en) 2003-08-12
NO20022246D0 (no) 2002-05-10

Similar Documents

Publication Publication Date Title
BR0015534A (pt) Tratamento da densidade mineral óssea subnormal
DK0880350T3 (da) Behandling af dissemineret sklerose
HUP0103839A3 (en) Use of certain drugs for treating nerve root injury
PL336788A1 (en) Probucol monoesters in treating circulatory system and inflammatory diseases
EP1005345A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF ALLERGIC ASTHMA AND OTHER CONDITIONS USING DESCARBOETHOXYLORATADINE
BG105534A (en) 5ht1 means and method for the treatment of migraine
BR9708362A (pt) Utilização de uma quantidade eficaz de um extrato e processo de tratamento cosmético
DE69833971D1 (de) Verfahren zur behandlung von alzheimerschen krankheit
AU5774699A (en) Human stearoyl-coa desaturase-related compositions and methods for treating skin disorders
NZ292940A (en) Use of an aromatase inhibitor and/or an androgen receptor anatonist as a cosmetic agent to reduce hair loss
AU6083301A (en) Treating eczema and/or psoriasis
AUPP674898A0 (en) A method of treatment
MY118986A (en) Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
GB2331301C (en) Galanin
ATE297753T1 (de) Verfahren und mittel zur schmerzbehandlung
AU4946699A (en) Method of treating meniere's disease and corresponding apparatus
NO984160D0 (no) Fremgangsmåte for behandling eller forebyggelse av interstitiell cystitt
HK1019702A1 (en) Use of (+)-alpha-(2,3-dimethoxyphenyl)ethyl]-4-piperidinemethanol in treating depressive disorders and bipolar disorders
ZA981781B (en) The use of levobupivacaine in treating migraine
HUP9900007A2 (hu) Készítmény baromfialom kezelésére
BA98363A (bs) Postupak i uredaj za tretiranje koze i tome slicno
EP0745597A3 (en) Novel melatonergic indanyl piperazines or homopiperazines
ATE282398T1 (de) Verfahren zum dauerwellen von menschlichen haaren
BR9509727A (pt) Processo de tratamento oral composição oral para tratar uma superfície oral uso e agente de tratamento oral
GB9800672D0 (en) Methods, uses and devices for antimicrobia treatment of mammalien skin

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.

B15K Others concerning applications: alteration of classification

Ipc: A61K 38/23 (2006.01), A61P 19/10 (2006.01), A61K 3